secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0001104659-25-071953
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE Phase 2b Repibresib vitiligo trial misses F-VASI50, terminates extension, seeks partner
--------------------------------------------------------------------------------

- Primary endpoint F-VASI50 at Week 24 not met: 19.5% for 3% vs 23.4% vehicle (p=0.1245).
- Key secondary endpoint F-VASI75 also not met (9.8% vs 6.4%, p=0.1468).
- Nominal statistical significance for 3% dose on percent CFB in F-VASI (-43.6% vs -25.6%, p=0.002) and T-VASI (-28.3% vs -16.2%, p=0.044).
- High vehicle effect and dropout rate in active arms (36.6% for 3% vs 10.6% vehicle); company ends trial extension phase.
- Preliminary cash $39.6M as of June 30, 2025; company seeking partner for Repibresib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000110465925071953/0001104659-25-071953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000110465925071953/tm2522042d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-071953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer